Global Histone Deacetylase Inhibitors Market : Industry Analysis and Forecast (2019-2026) – By Class, Application, End User, and Region.

Global Histone Deacetylase Inhibitors Market : Industry Analysis and Forecast (2019-2026) – By Class, Application, End User, and Region.

Market Scenario

Global Histone Deacetylase Inhibitors Market was valued US$ XX  Mn in 2018 and is expected to reach US$ 1564.4 Mn by 2026, at CAGR of XX% during forecast period. Global Histone Deacetylase Inhibitors Market, by End User Rapidly increasing number of cancer patients across the nation and the need to improve the effectiveness of new advance therapies are the prime growth drivers of histone deacetylase inhibitors market. Also, increased R&D activities being carried out for the treatment of cancers & other diseases and increase in collaborations and investments in the HDAC manufacturing are proving to be the huge opportunities for the growth of this market. At the same time, reimbursement and uncertainty issues in regards to HDAC inhibitors are the limiting factor for the histone deacetylase inhibitors market. The development of wearable technology and the incorporation of smart devices in fitness machines and gyms are boosting the histone deacetylase inhibitors market demand. Connected devices, such as activity trackers & smart watches, track the consumers’ performance and actual exercise timings. Additionally, the development of smart gyms and increasing consumption of household fitness machines help to raise the demand for histone deacetylase inhibitors. A number of manufacturers have launched smart exercising machines, such as Bluetooth dumbbells & connected rowing machines, to enhance the consumer experiences. Such as, Peloton introduced its home cardio bike that comprises a 22-inch touch screen display and supports the iOS application for tracking the performance.At the same time uncertainty issues and inadequate reimbursement for histone deacetylase inhibitors are likely to restrain the global market during the forecast period. Additionally, high costs associated due to the technical advancements therapies for cancer treatmentacross the globe. According to the end-user segment, oncology clinics end-user segment is projected to hold the highest market share because of the increasing adoption of innovative therapies for cancer treatment and the increasing incidence of cancer across the world. Similarly, growing expenditure on R&D activities by pharmaceutical companies and increasing government funding for such activities is likely to boost the growth for the histone deacetylase inhibitors market during the forecast period. Based on region, North America histone deacetylase inhibitors market is expected to hold the largest market share due to an increase in R&D for the development of drugs, an increase in the prevalence of cancer and neurological disorders, and high usage of HDAC products are likely to the boost the market. Europe histone deacetylase inhibitors market is growing due to the rise in the aging population results to an increase in the prevalence of neurological disorders, growth in demand for higher treatments, and pipeline drugs under the range of stages of treatment are bolster the market. The market appears to be moderately focused on the presence of a few market players. Companies are concentrating on research on several other types of cancers using HDAC inhibitors due to their high target affinity and specificity. This market research report will help customers identify new growth opportunities and design growth strategies by providing a comprehensive analysis of the competitive landscape and present information on the demand offered by companies. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the histone deacetylase inhibitors Market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the histone deacetylase inhibitors Market.

Scope of Global Histone Deacetylase Inhibitors Market:

Global Histone Deacetylase Inhibitors Market, by Class:

• Class I HDACs • Class II HDACs • Class III HDACs • Class IV HDACs

Global Histone Deacetylase Inhibitors Market, by Application:

• Oncology • Neurology • Others

Global Histone Deacetylase Inhibitors Market, by End User:

• Hospitals • Oncology Clinics • Others

Global Histone Deacetylase Inhibitors Market, by Region:

• North America • Europe • Asia-Pacific • Central & South America • Middle East & Africa

Key Players Operated in Market Include:

• Celgene Corporation • Celleron Therapeutics Ltd • Eisai Co., Ltd. • Novartis International AG • Acetylon Pharmaceuticals, Inc. • AstraZeneca plc. • Merck & Co., Inc. • Pfizer Inc. • AstraZeneca plc • Envivo Pharmaceuticals Global Bio-Banks Market

Table of Contents

Table of Content

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.2. Secondary data 2.3.3. Secondary Sources 2.3.4. Primary Research 2.3.5. Data from Primary Sources 2.3.6. Breakdown of Primary Sources 3. Executive Summary:  Global Histone Deacetylase Inhibitors Market, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends in Global Histone Deacetylase Inhibitors Market and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Histone Deacetylase Inhibitors Market Analysis and Forecast 6.1. Global Histone Deacetylase Inhibitors Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Histone Deacetylase Inhibitors Market Analysis and Forecast, By Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Histone Deacetylase Inhibitors Market Value Share Analysis, By Class 7.4. Global Histone Deacetylase Inhibitors Market Size (US$ Mn) Forecast, By Class 7.5. Global Histone Deacetylase Inhibitors Market Analysis, By Class 7.6. Global Histone Deacetylase Inhibitors Market Attractiveness Analysis, By Class 8. Global Histone Deacetylase Inhibitors Market Analysis and Forecast, By application 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Histone Deacetylase Inhibitors Market Value Share Analysis, By application 8.4. Global Histone Deacetylase Inhibitors Market Size (US$ Mn) Forecast, By application 8.5. Global Histone Deacetylase Inhibitors Market Analysis, By application 8.6. Global Histone Deacetylase Inhibitors Market Attractiveness Analysis, By application 9. Global Histone Deacetylase Inhibitors Market Analysis and Forecast, by End User 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Histone Deacetylase Inhibitors Market Value Share Analysis, by End User 9.4. Global Histone Deacetylase Inhibitors Market Size (US$ Mn) Forecast, by End User 9.5. Global Histone Deacetylase Inhibitors Market Analysis, by End User 9.6. Global Histone Deacetylase Inhibitors Market Attractiveness Analysis, by End User 10. Global Histone Deacetylase Inhibitors Market Analysis, by Region 10.1. Global Histone Deacetylase Inhibitors Market Value Share Analysis, by Region 10.2. Global Histone Deacetylase Inhibitors Market Size (US$ Mn) Forecast, by Region 10.3. Global Histone Deacetylase Inhibitors Market Attractiveness Analysis, by Region 11. North America Histone Deacetylase Inhibitors Market Analysis 11.1. Key Findings 11.2. North America Histone Deacetylase Inhibitors Market Overview 11.3. North America Histone Deacetylase Inhibitors Market Value Share Analysis, By Class 11.4. North America Histone Deacetylase Inhibitors Market Forecast, By Class 11.4.1. Class I HDACs 11.4.2. Class II HDACs 11.4.3. Class III HDACs 11.4.4. Class IV HDACs 11.5. North America Histone Deacetylase Inhibitors Market Value Share Analysis, By application 11.6. North America Histone Deacetylase Inhibitors Market Forecast, By application 11.6.1. Oncology 11.6.2. Neurology 11.6.3. Others 11.7. North America Histone Deacetylase Inhibitors Market Value Share Analysis, by End User 11.8. North America Histone Deacetylase Inhibitors Market Forecast, by End User 11.8.1. Hospitals 11.8.2. Oncology Clinics 11.8.3. Others 11.9. North America Histone Deacetylase Inhibitors Market Value Share Analysis, by Country 11.10. North America Histone Deacetylase Inhibitors Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Histone Deacetylase Inhibitors Market Analysis, by Country 11.12. U.S. Histone Deacetylase Inhibitors Market Forecast, By Class 11.12.1. Class I HDACs 11.12.2. Class II HDACs 11.12.3. Class III HDACs 11.12.4. Class IV HDACs 11.13. U.S. Histone Deacetylase Inhibitors Market Forecast, By application 11.13.1. Oncology 11.13.2. Neurology 11.13.3. Others 11.14. U.S. Histone Deacetylase Inhibitors Market Forecast, by End User 11.14.1. Hospitals 11.14.2. Oncology Clinics 11.14.3. Others 11.15. Canada Histone Deacetylase Inhibitors Market Forecast, By Class 11.15.1. Class I HDACs 11.15.2. Class II HDACs 11.15.3. Class III HDACs 11.15.4. Class IV HDACs 11.16. Canada Histone Deacetylase Inhibitors Market Forecast, By application 11.16.1. Oncology 11.16.2. Neurology 11.16.3. Others 11.17. Canada Histone Deacetylase Inhibitors Market Forecast, by End User 11.17.1. Hospitals 11.17.2. Oncology Clinics 11.17.3. Others 11.18. North America Histone Deacetylase Inhibitors Market Attractiveness Analysis 11.18.1. By Class 11.18.2. By application 11.18.3. By End User 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Development 12. Europe Histone Deacetylase Inhibitors Market Analysis 12.1. Key Findings 12.2. Europe Histone Deacetylase Inhibitors Market Overview 12.3. Europe Histone Deacetylase Inhibitors Market Value Share Analysis, By Class 12.4. Europe Histone Deacetylase Inhibitors Market Forecast, By Class 12.4.1. Class I HDACs 12.4.2. Class II HDACs 12.4.3. Class III HDACs 12.4.4. Class IV HDACs 12.5. Europe Histone Deacetylase Inhibitors Market Value Share Analysis, By application 12.6. Europe Histone Deacetylase Inhibitors Market Forecast, By application 12.6.1. Oncology 12.6.2. Neurology 12.6.3. Others 12.7. Europe Histone Deacetylase Inhibitors Market Value Share Analysis, by End User 12.8. Europe Histone Deacetylase Inhibitors Market Forecast, by End User 12.8.1. Hospitals 12.8.2. Oncology Clinics 12.8.3. Others 12.9. Europe Histone Deacetylase Inhibitors Market Value Share Analysis, by Country 12.10. Europe Histone Deacetylase Inhibitors Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Histone Deacetylase Inhibitors Market Analysis, by Country 12.12. Germany Histone Deacetylase Inhibitors Market Forecast, By Class 12.12.1. Class I HDACs 12.12.2. Class II HDACs 12.12.3. Class III HDACs 12.12.4. Class IV HDACs 12.13. Germany Histone Deacetylase Inhibitors Market Forecast, By application 12.13.1. Oncology 12.13.2. Neurology 12.13.3. Others 12.14. Germany Histone Deacetylase Inhibitors Market Forecast, by End User 12.14.1. Hospitals 12.14.2. Oncology Clinics 12.14.3. Others 12.15. U.K. Histone Deacetylase Inhibitors Market Forecast, By Class 12.15.1. Class I HDACs 12.15.2. Class II HDACs 12.15.3. Class III HDACs 12.15.4. Class IV HDACs 12.16. U.K. Histone Deacetylase Inhibitors Market Forecast, By application 12.16.1. Oncology 12.16.2. Neurology 12.16.3. Others 12.17. U.K. Histone Deacetylase Inhibitors Market Forecast, by End User 12.17.1. Hospitals 12.17.2. Oncology Clinics 12.17.3. Others 12.18. France Histone Deacetylase Inhibitors Market Forecast, By Class 12.18.1. Class I HDACs 12.18.2. Class II HDACs 12.18.3. Class III HDACs 12.18.4. Class IV HDACs 12.19. France Histone Deacetylase Inhibitors Market Forecast, By application 12.19.1. Oncology 12.19.2. Neurology 12.19.3. Others 12.20. France Histone Deacetylase Inhibitors Market Forecast, by End User 12.20.1. Hospitals 12.20.2. Oncology Clinics 12.20.3. Others 12.21. Italy Histone Deacetylase Inhibitors Market Forecast, By Class 12.21.1. Class I HDACs 12.21.2. Class II HDACs 12.21.3. Class III HDACs 12.21.4. Class IV HDACs 12.22. Italy Histone Deacetylase Inhibitors Market Forecast, By application 12.22.1. Oncology 12.22.2. Neurology 12.22.3. Others 12.23. Italy Histone Deacetylase Inhibitors Market Forecast, by End User 12.23.1. Hospitals 12.23.2. Oncology Clinics 12.23.3. Others 12.24. Spain Histone Deacetylase Inhibitors Market Forecast, By Class 12.24.1. Class I HDACs 12.24.2. Class II HDACs 12.24.3. Class III HDACs 12.24.4. Class IV HDACs 12.25. Spain Histone Deacetylase Inhibitors Market Forecast, By application 12.25.1. Oncology 12.25.2. Neurology 12.25.3. Others 12.26. Spain Histone Deacetylase Inhibitors Market Forecast, by End User 12.26.1. Hospitals 12.26.2. Oncology Clinics 12.26.3. Others 12.27. Rest of Europe Histone Deacetylase Inhibitors Market Forecast, By Class 12.27.1. Class I HDACs 12.27.2. Class II HDACs 12.27.3. Class III HDACs 12.27.4. Class IV HDACs 12.28. Rest of Europe Histone Deacetylase Inhibitors Market Forecast, By application 12.28.1. Oncology 12.28.2. Neurology 12.28.3. Others 12.29. Rest of Europe Histone Deacetylase Inhibitors Market Forecast, by End User 12.29.1. Hospitals 12.29.2. Oncology Clinics 12.29.3. Others 12.30. Europe Histone Deacetylase Inhibitors Market Attractiveness Analysis 12.30.1. By Class 12.30.2. By application 12.30.3. By End User 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Development 13. Asia Pacific Histone Deacetylase Inhibitors Market Analysis 13.1. Key Findings 13.2. Asia Pacific Histone Deacetylase Inhibitors Market Overview 13.3. Asia Pacific Histone Deacetylase Inhibitors Market Value Share Analysis, By Class 13.4. Asia Pacific Histone Deacetylase Inhibitors Market Forecast, By Class 13.4.1. Class I HDACs 13.4.2. Class II HDACs 13.4.3. Class III HDACs 13.4.4. Class IV HDACs 13.5. Asia Pacific Histone Deacetylase Inhibitors Market Value Share Analysis, By application 13.6. Asia Pacific Histone Deacetylase Inhibitors Market Forecast, By application 13.6.1. Oncology 13.6.2. Neurology 13.6.3. Others 13.7. Asia Pacific Histone Deacetylase Inhibitors Market Value Share Analysis, by End User 13.8. Asia Pacific Histone Deacetylase Inhibitors Market Forecast, by End User 13.8.1. Hospitals 13.8.2. Oncology Clinics 13.8.3. Others 13.9. Asia Pacific Histone Deacetylase Inhibitors Market Value Share Analysis, by Country 13.10. Asia Pacific Histone Deacetylase Inhibitors Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Histone Deacetylase Inhibitors Market Analysis, by Country 13.12. China Histone Deacetylase Inhibitors Market Forecast, By Class 13.12.1. Class I HDACs 13.12.2. Class II HDACs 13.12.3. Class III HDACs 13.12.4. Class IV HDACs 13.13. China Histone Deacetylase Inhibitors Market Forecast, By application 13.13.1. Oncology 13.13.2. Neurology 13.13.3. Others 13.14. China Histone Deacetylase Inhibitors Market Forecast, by End User 13.14.1. Hospitals 13.14.2. Oncology Clinics 13.14.3. Others 13.15. India Histone Deacetylase Inhibitors Market Forecast, By Class 13.15.1. Class I HDACs 13.15.2. Class II HDACs 13.15.3. Class III HDACs 13.15.4. Class IV HDACs 13.16. India Histone Deacetylase Inhibitors Market Forecast, By application 13.16.1. Oncology 13.16.2. Neurology 13.16.3. Others 13.17. India Histone Deacetylase Inhibitors Market Forecast, by End User 13.17.1. Hospitals 13.17.2. Oncology Clinics 13.17.3. Others 13.18. Japan Histone Deacetylase Inhibitors Market Forecast, By Class 13.18.1. Class I HDACs 13.18.2. Class II HDACs 13.18.3. Class III HDACs 13.18.4. Class IV HDACs 13.19. Japan Histone Deacetylase Inhibitors Market Forecast, By application 13.19.1. Oncology 13.19.2. Neurology 13.19.3. Others 13.20. Japan Histone Deacetylase Inhibitors Market Forecast, by End User 13.20.1. Hospitals 13.20.2. Oncology Clinics 13.20.3. Others 13.21. ASEAN Histone Deacetylase Inhibitors Market Forecast, By Class 13.21.1. Class I HDACs 13.21.2. Class II HDACs 13.21.3. Class III HDACs 13.21.4. Class IV HDACs 13.22. ASEAN Histone Deacetylase Inhibitors Market Forecast, By application 13.22.1. Oncology 13.22.2. Neurology 13.22.3. Others 13.23. ASEAN Histone Deacetylase Inhibitors Market Forecast, by End User 13.23.1. Hospitals 13.23.2. Oncology Clinics 13.23.3. Others 13.24. Rest of Asia Pacific Histone Deacetylase Inhibitors Market Forecast, By Class 13.24.1. Class I HDACs 13.24.2. Class II HDACs 13.24.3. Class III HDACs 13.24.4. Class IV HDACs 13.25. Rest of Asia Pacific Histone Deacetylase Inhibitors Market Forecast, By application 13.25.1. Oncology 13.25.2. Neurology 13.25.3. Others 13.26. Rest of Asia Pacific Histone Deacetylase Inhibitors Market Forecast, by End User 13.26.1. Hospitals 13.26.2. Oncology Clinics 13.26.3. Others 13.27. Asia Pacific Histone Deacetylase Inhibitors Market Attractiveness Analysis 13.27.1. By Class 13.27.2. By application 13.27.3. By End User 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Development 14. Middle East & Africa Histone Deacetylase Inhibitors Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Histone Deacetylase Inhibitors Market Overview 14.3. Middle East & Africa Histone Deacetylase Inhibitors Market Value Share Analysis, By Class 14.4. Middle East & Africa Histone Deacetylase Inhibitors Market Forecast, By Class 14.4.1. Class I HDACs 14.4.2. Class II HDACs 14.4.3. Class III HDACs 14.4.4. Class IV HDACs 14.5. Middle East & Africa Histone Deacetylase Inhibitors Market Value Share Analysis, By application 14.6. Middle East & Africa Histone Deacetylase Inhibitors Market Forecast, By application 14.6.1. Oncology 14.6.2. Neurology 14.6.3. Others 14.7. Middle East & Africa Histone Deacetylase Inhibitors Market Value Share Analysis, by End User 14.8. Middle East & Africa Histone Deacetylase Inhibitors Market Forecast, by End User 14.8.1. Hospitals 14.8.2. Oncology Clinics 14.8.3. Others 14.9. Middle East & Africa Histone Deacetylase Inhibitors Market Value Share Analysis, by Country 14.10. Middle East & Africa Histone Deacetylase Inhibitors Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Histone Deacetylase Inhibitors Market Analysis, by Country 14.12. GCC Histone Deacetylase Inhibitors Market Forecast, By Class 14.12.1. Class I HDACs 14.12.2. Class II HDACs 14.12.3. Class III HDACs 14.12.4. Class IV HDACs 14.13. GCC Histone Deacetylase Inhibitors Market Forecast, By application 14.13.1. Oncology 14.13.2. Neurology 14.13.3. Others 14.14. GCC Histone Deacetylase Inhibitors Market Forecast, by End User 14.14.1. Hospitals 14.14.2. Oncology Clinics 14.14.3. Others 14.15. South Africa Histone Deacetylase Inhibitors Market Forecast, By Class 14.15.1. Class I HDACs 14.15.2. Class II HDACs 14.15.3. Class III HDACs 14.15.4. Class IV HDACs 14.16. South Africa Histone Deacetylase Inhibitors Market Forecast, By application 14.16.1. Oncology 14.16.2. Neurology 14.16.3. Others 14.17. South Africa Histone Deacetylase Inhibitors Market Forecast, by End User 14.17.1. Hospitals 14.17.2. Oncology Clinics 14.17.3. Others 14.18. Rest of Middle East & Africa Histone Deacetylase Inhibitors Market Forecast, By Class 14.18.1. Class I HDACs 14.18.2. Class II HDACs 14.18.3. Class III HDACs 14.18.4. Class IV HDACs 14.19. Rest of Middle East & Africa Histone Deacetylase Inhibitors Market Forecast, By application 14.19.1. Oncology 14.19.2. Neurology 14.19.3. Others 14.20. Rest of Middle East & Africa Histone Deacetylase Inhibitors Market Forecast, by End User 14.20.1. Hospitals 14.20.2. Oncology Clinics 14.20.3. Others 14.21. Middle East & Africa Histone Deacetylase Inhibitors Market Attractiveness Analysis 14.21.1. By Class 14.21.2. By application 14.21.3. By End User 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Development 15. South America Histone Deacetylase Inhibitors Market Analysis 15.1. Key Findings 15.2. South America Histone Deacetylase Inhibitors Market Overview 15.3. South America Histone Deacetylase Inhibitors Market Value Share Analysis, By Class 15.4. South America Histone Deacetylase Inhibitors Market Forecast, By Class 15.4.1. Class I HDACs 15.4.2. Class II HDACs 15.4.3. Class III HDACs 15.4.4. Class IV HDACs 15.5. South America Histone Deacetylase Inhibitors Market Value Share Analysis, By application 15.6. South America Histone Deacetylase Inhibitors Market Forecast, By application 15.6.1. Oncology 15.6.2. Neurology 15.6.3. Others 15.7. South America Histone Deacetylase Inhibitors Market Value Share Analysis, by End User 15.8. South America Histone Deacetylase Inhibitors Market Forecast, by End User 15.8.1. Hospitals 15.8.2. Oncology Clinics 15.8.3. Others 15.9. South America Histone Deacetylase Inhibitors Market Value Share Analysis, by Country 15.10. South America Histone Deacetylase Inhibitors Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Histone Deacetylase Inhibitors Market Analysis, by Country 15.12. Brazil Histone Deacetylase Inhibitors Market Forecast, By Class 15.12.1. Class I HDACs 15.12.2. Class II HDACs 15.12.3. Class III HDACs 15.12.4. Class IV HDACs 15.13. Brazil Histone Deacetylase Inhibitors Market Forecast, By application 15.13.1. Oncology 15.13.2. Neurology 15.13.3. Others 15.14. Brazil Histone Deacetylase Inhibitors Market Forecast, by End User 15.14.1. Hospitals 15.14.2. Oncology Clinics 15.14.3. Others 15.15. Mexico Histone Deacetylase Inhibitors Market Forecast, By Class 15.15.1. Class I HDACs 15.15.2. Class II HDACs 15.15.3. Class III HDACs 15.15.4. Class IV HDACs 15.16. Mexico Histone Deacetylase Inhibitors Market Forecast, By application 15.16.1. Oncology 15.16.2. Neurology 15.16.3. Others 15.17. Mexico Histone Deacetylase Inhibitors Market Forecast, by End User 15.17.1. Hospitals 15.17.2. Oncology Clinics 15.17.3. Others 15.18. Rest of South America Histone Deacetylase Inhibitors Market Forecast, By Class 15.18.1. Class I HDACs 15.18.2. Class II HDACs 15.18.3. Class III HDACs 15.18.4. Class IV HDACs 15.19. Rest of South America Histone Deacetylase Inhibitors Market Forecast, By application 15.19.1. Oncology 15.19.2. Neurology 15.19.3. Others 15.20. Rest of South America Histone Deacetylase Inhibitors Market Forecast, by End User 15.20.1. Hospitals 15.20.2. Oncology Clinics 15.20.3. Others 15.21. South America Histone Deacetylase Inhibitors Market Attractiveness Analysis 15.21.1. By Class 15.21.2. By application 15.21.3. By End User 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Development 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Celgene Corporation 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Celleron Therapeutics Ltd 16.3.3. Eisai Co., Ltd. 16.3.4. Novartis International AG 16.3.5. Acetylon Pharmaceuticals, Inc. 16.3.6. AstraZeneca plc. 16.3.7. Merck & Co., Inc. 16.3.8. Pfizer Inc. 16.3.9. AstraZeneca plc 16.3.10. Envivo Pharmaceuticals 17. Primary Key Insights

About This Report

Report ID30506
Published DateNov 2019
Contact Us
Call Now